MTIP targets CRF1R
Evidence from:
primary |
all sources
Evidence (2 sources)
MTIP is a novel, orally available and brain penetrant CRH‑R1 antagonist
confidence: 0.96
MTIP inhibited 125I-sauvagine binding to cloned hCRH-R1 with sub-nanomolar affinities
confidence: 0.95